XTX Topco Ltd Buys Shares of 3,746 Ascendis Pharma A/S (NASDAQ:ASND)

Key Points

• XTX Topco Ltd acquired a new position in Ascendis Pharma A/S, purchasing 3,746 shares valued at approximately $584,000 during the first quarter of the year.
• Analysts have set new price targets for Ascendis Pharma A/S, with estimates ranging from $200.00 to $280.00, and the stock currently holds an average rating of "Moderate Buy."
• Ascendis Pharma's stock has shown significant price movement, opening at $186.59 while having a 12-month range from $111.09 to $186.89.

XTX Topco Ltd purchased a new stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the first quarter, according to its most recent filing with the SEC. The fund purchased 3,746 shares of the biotechnology company's stock, valued at approximately $584,000.

A number of other institutional investors have also made changes to their positions in ASND. TD Asset Management Inc boosted its holdings in Ascendis Pharma A/S by 1.1% in the first quarter. TD Asset Management Inc now owns 343,390 shares of the biotechnology company's stock worth $53,521,000 after purchasing an additional 3,738 shares during the period. Gilbert & Cook Inc. lifted its position in shares of Ascendis Pharma A/S by 49.7% in the 1st quarter. Gilbert & Cook Inc. now owns 6,619 shares of the biotechnology company's stock worth $1,032,000 after buying an additional 2,198 shares during the last quarter. Diversify Advisory Services LLC acquired a new position in shares of Ascendis Pharma A/S in the 1st quarter valued at about $332,000. Massachusetts Financial Services Co. MA grew its position in shares of Ascendis Pharma A/S by 0.6% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 1,877,917 shares of the biotechnology company's stock valued at $292,692,000 after buying an additional 10,366 shares during the last quarter. Finally, Sigma Planning Corp acquired a new stake in Ascendis Pharma A/S during the first quarter worth about $236,000.

Ascendis Pharma A/S Stock Up 0.6%

Shares of ASND traded up $1.14 during trading hours on Friday, reaching $191.49. The company's stock had a trading volume of 1,554,046 shares, compared to its average volume of 494,592. The company has a 50 day moving average of $173.47 and a two-hundred day moving average of $158.42. The firm has a market cap of $11.71 billion, a price-to-earnings ratio of -30.49 and a beta of 0.41. Ascendis Pharma A/S has a 1-year low of $111.09 and a 1-year high of $199.99.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its earnings results on Thursday, August 7th. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.42) by $0.49. The company had revenue of $216.28 million for the quarter, compared to analyst estimates of $163.17 million. As a group, analysts forecast that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Analysts Set New Price Targets

ASND has been the subject of several recent research reports. Wells Fargo & Company reaffirmed an "overweight" rating and set a $295.00 target price (up from $289.00) on shares of Ascendis Pharma A/S in a report on Friday. Wedbush upped their price objective on Ascendis Pharma A/S from $212.00 to $220.00 and gave the stock an "outperform" rating in a research note on Friday. Cantor Fitzgerald raised their target price on Ascendis Pharma A/S from $200.00 to $203.00 and gave the company an "overweight" rating in a research note on Friday. Oppenheimer reissued an "outperform" rating and set a $224.00 price target (up previously from $215.00) on shares of Ascendis Pharma A/S in a report on Friday, June 13th. Finally, Royal Bank Of Canada increased their price objective on shares of Ascendis Pharma A/S from $210.00 to $230.00 and gave the stock an "outperform" rating in a report on Friday. One investment analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $236.67.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.